In a U-turn from a decision two weeks ago, the FDA – citing new safety events – said the vaccine is a ‘danger to health’.

The U.S. Food and Drug Administration (USFDA) has suspended the biologics license of Ixchiq (Chikungunya Vaccine, Live), ...

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...

The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of Ixchiq in the United States. The suspension follows the US FDA’s decision on August 6, 20251 ...

The United States Food and Drug Administration (FDA) has suspended the licence of one of the two chikungunya vaccines ...

The U.S. FDA has suspended the license for Valneva’s chikungunya vaccine Ixchiq after reports of severe side effects, ...

By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is ...

US health authorities have suspended the licence for the Ixchiq vaccine against the chikungunya virus following reports of “serious adverse events”, the drug’s French maker said Monday.

The decision to suspend the Ixchiq vaccine comes as public health experts warn the mosquito-spread virus could pose a future pandemic threat.

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...